Multidrug-resistant tuberculosis in europe, 2010-2011

Gunar Günther, Frank Van Leth, Sofa Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Danilovits, Martin Dedicoat, Raquel Duarte, Gina Gualano, Heinke Kunst, Wiel De Lange, Vaira Leimane, Cecile Magis-Escurra, Anne Marie McLaughlin, Inge MuylleVeronika Polcová, Emanuele Pontali, Christina Popa, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Piret Viiklepp, Christoph Lange, Marcel Rowhani, Vera Avchinko, Dzimitry Katovich, Dzimitri Klimuk, Valentina Lobik, Zoya Rohaya, Alexander Shirochyn, Jana Kotrbova, Martina Vasakova, Aase Bengard Andersen, Nelleke Smitsman, Ralf Mütterlein, Saverio De Lorenzo, Liga Rusmane, Ana Donica, Ilie Cernenco, Vera Dubceac, Femke Cuppen, Inge De Guchtenaire, Robert Meesters, Mark Te Pas, Bram Prins, Ana Atunes, Dan Gainaru, Elmira Ibraim, Mirela Tigau, Juan Cayla, Laia Fina, Maria Luiza De Souza Galvao, José Maldonado

Research output: Contribution to journalArticlepeer-review

Abstract

Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to >1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fuoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

Original languageEnglish
Pages (from-to)409-416
Number of pages8
JournalEmerging Infectious Diseases
Volume21
Issue number3
DOIs
Publication statusPublished - 2015

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Epidemiology

Fingerprint

Dive into the research topics of 'Multidrug-resistant tuberculosis in europe, 2010-2011'. Together they form a unique fingerprint.

Cite this